Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: the age-related patterns for high-risk and low-risk types - PubMed (original) (raw)
. 2000 Jul 15;87(2):221-7.
Affiliations
- PMID: 10861478
Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: the age-related patterns for high-risk and low-risk types
M V Jacobs et al. Int J Cancer. 2000.
Abstract
Before guidelines can be set for the use of high-risk human papillomavirus (HR HPV) testing in cervical cancer screening and vaccine preparation, age-related prevalence of HR HPV types in cytologically normal smears has to be known. Therefore, in a cross-sectional study the prevalence of 37 different HPV genotypes and putatively unidentified HPV types was determined in 3,305 cytologically normal cervical smears from the general female population (15-69 years of age) using an HPV general primer GP5+/bioGP6+ mediated PCR assay. Subsequently, HPV-positive cervical smears were typed for 19 HR and 18 low-risk (LR) HPVs with an enzyme immunoassay using HPV type-specific oligoprobes in cocktails and individually, respectively. Overall, -HR and -LR HPV prevalences appeared to be of 4.6%, 3.3%, and 1.0%, respectively. Twenty-six different HPV types were detected in the 152 HPV-positive samples, the most prevalent types being HPV 16, 31, and 18. With regard to age, a peak prevalence of 19.6% for all HPVs was found in women 25-29 years of age, which declined to a mean of 4.3% in women over 30 years. With regard cytologically normal cervical smears (n = 3, 011) of women participating in the population-based screening program in the Netherlands (30 to 60 years), all HR HPVs showed decreased occurrence with increasing age, whereas the prevalence of LR HPV types remained constant. We suggest that screening for abnormal cytology implies screening for HR HPV infections and the subsequent treatment results in a decline of HR HPV prevalence in contrast to LR HPV prevalence during the years of screening.
Copyright 2000 Wiley-Liss, Inc.
Similar articles
- Prevalence of high-risk human papillomavirus type 16/18 infection among women with normal cytology: risk factor analysis and implications for screening and prophylaxis.
Gupta S, Sodhani P, Sharma A, Sharma JK, Halder K, Charchra KL, Sardana S, Singh V, Sehgal A, Das BC. Gupta S, et al. Cytopathology. 2009 Aug;20(4):249-55. doi: 10.1111/j.1365-2303.2008.00611.x. Epub 2008 Oct 24. Cytopathology. 2009. PMID: 19018810 - Pre-vaccination prevalence of infections with 25 non-high-risk human papillomavirus types among 1,000 Slovenian women in cervical cancer screening.
Učakar V, Poljak M, Oštrbenk A, Klavs I. Učakar V, et al. J Med Virol. 2014 Oct;86(10):1772-9. doi: 10.1002/jmv.23997. Epub 2014 Jun 30. J Med Virol. 2014. PMID: 24978445 - Age-specific detection of high risk HPV DNA in cytologically normal, computer-imaged ThinPrep Pap samples.
Cibas ES, Hong X, Crum CP, Feldman S. Cibas ES, et al. Gynecol Oncol. 2007 Mar;104(3):702-6. doi: 10.1016/j.ygyno.2006.10.048. Epub 2006 Dec 5. Gynecol Oncol. 2007. PMID: 17150245 - Prevalence and genotype distribution of multiple human papillomavirus infection in the uterine cervix: a 7.5-year longitudinal study in a routine cytology-based screening population in West Germany.
Kovács K, Varnai AD, Bollmann M, Bankfalvi A, Szendy M, Speich N, Schmitt C, Pajor L, Bollmann R. Kovács K, et al. J Med Virol. 2008 Oct;80(10):1814-23. doi: 10.1002/jmv.21282. J Med Virol. 2008. PMID: 18712836 - HPV genotype prevalence in Australian women undergoing routine cervical screening by cytology status prior to implementation of an HPV vaccination program.
Tabrizi SN, Brotherton JM, Stevens MP, Condon JR, McIntyre P, Smith D, Garland SM; WHINURS group. Tabrizi SN, et al. J Clin Virol. 2014 Jul;60(3):250-6. doi: 10.1016/j.jcv.2014.04.013. Epub 2014 May 5. J Clin Virol. 2014. PMID: 24854516
Cited by
- Population-based age- and type-specific prevalence of human papillomavirus among non-vaccinated women aged 30 years and above in Germany.
Liang LA, Tanaka LF, Radde K, Bussas U, Ikenberg H, Heideman DAM, Meijer CJLM, Blettner M, Klug SJ. Liang LA, et al. BMC Infect Dis. 2024 Sep 19;24(1):1008. doi: 10.1186/s12879-024-09827-7. BMC Infect Dis. 2024. PMID: 39300354 Free PMC article. - Human papillomavirus vaccine effect against human papillomavirus infection in Rwanda: evidence from repeated cross-sectional cervical-cell-based surveys.
Sayinzoga F, Tenet V, Heideman DAM, Sibomana H, Umulisa MC, Franceschi S, Hakizimana JD, Clifford GM, Baussano I. Sayinzoga F, et al. Lancet Glob Health. 2023 Jul;11(7):e1096-e1104. doi: 10.1016/S2214-109X(23)00193-6. Epub 2023 May 16. Lancet Glob Health. 2023. PMID: 37207683 Free PMC article. - Human papillomavirus testing on self-collected samples to detect high-grade cervical lesions in rural Bhutan: The REACH-Bhutan study.
Clifford GM, Baussano I, Heideman DAM, Tshering S, Choden T, Lazzarato F, Tenet V, Franceschi S, Darragh TM, Tobgay T, Tshomo U. Clifford GM, et al. Cancer Med. 2023 May;12(10):11828-11837. doi: 10.1002/cam4.5851. Epub 2023 Mar 31. Cancer Med. 2023. PMID: 36999740 Free PMC article. - Prevalence of HPV and Assessing Type-Specific HPV Testing in Cervical High-Grade Squamous Intraepithelial Lesions in Poland.
Przybylski M, Pruski D, Wszołek K, de Mezer M, Żurawski J, Jach R, Millert-Kalińska S. Przybylski M, et al. Pathogens. 2023 Feb 19;12(2):350. doi: 10.3390/pathogens12020350. Pathogens. 2023. PMID: 36839622 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Other Literature Sources
Medical
Miscellaneous